Lewis R. Silverman, Pierre Fenaux, Ghulam J. Mufti, Valeria Santini, Eva Hellström-Lindberg, Norbert Gattermann, Guillermo Sanz, Alan F. List, Steven D. Gore and John F. Seymour Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes Cancer 117
Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25774
Continued azacitidine therapy is associated with a quantitative increase in response to a higher response category. Therefore, continued azacitidine therapy may enhance clinical benefit in patients with higher-risk myelodysplastic syndromes.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field